Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Hormone Receptor Positive Tumor|HER 2 Negative Breast Cancer
Interventions: COMBINATION_PRODUCT: Ribociclib and aromatase inhibitor or fulvestrant|COMBINATION_PRODUCT: Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab
Sponsor: iOMEDICO AG
Collaborators: Novartis Pharmaceuticals